HF1K16

DRUG2 trials

Sponsors

HighField Biopharmaceuticals Corporation

Conditions

AdultGliomaHealthy

Phase 1

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

CompletedNCT05386823

HighField Biopharmaceuticals CorporationHealthy

Start: 2021-03-20End: 2021-08-04Updated: 2024-05-23

Phase 2

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

RecruitingNCT07678684

HighField Biopharmaceuticals CorporationAdult, Glioma

Start: 2026-06-30End: 2028-12-31Target: 30Updated: 2026-07-10